Biotech Healthcare Announces Korean Good and Manufacturing Practices Approval

Biotech Healthcare has received KGMP (Korean Goods & Manufacturing Practice) approval, allowing its ophthalmic products to be accessible to South Korean markets.

“Today when we talk about addressing the urgent need of global eye care problems, may that be cataracts or the myopic wave that the world population is witnessing, the focus for us is the make best treatment options available as well as accessible to people,” Devendra Khalsa, Head of Marketing & Clinical Affairs at Biotech Healthcare, said in a company news release.

Biotech Healthcare aims to be a major contributor in providing avoidable blindness and vision impairment solutions through its range of high quality IOLs for treating cataracts and astigmatism, refractive IOLs treating myopia, ophthalmic solutions, and equipment used for surgeries and diagnosis.

Phakic IOLs from Biotech Healthcare has been certified by KFDA (Korea Food and Drug Administration) making its products accessible to people in South Korea.